mnk-20220315
0001567892false00015678922022-03-152022-03-1500015678922021-03-102021-03-10


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 15, 2022
 
Mallinckrodt plc
(Exact name of registrant as specified in its charter)
Ireland001-3580398-1088325
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
 Identification No.)
College Business & Technology Park, Cruiserath,
Blanchardstown, Dublin 15, Ireland
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code:  +353 1 696 0000

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: 
(Title of each class)
Ordinary shares, par value $0.20 per share
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 2.02    Results of Operations and Financial Condition.
On March 15, 2022, Mallinckrodt plc (the "Company" or "Mallinckrodt") provided its financial results for the quarter and year ended December 31, 2021 in the attached Exhibit 99.1.
The information in this Current Report on Form 8-K, including Exhibit 99.1, should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as otherwise expressly set forth by specific reference in such a filing.
NON-GAAP FINANCIAL MEASURES
Exhibit 99.1 contains financial measures, including adjusted EBITDA and net sales growth on a constant-currency basis, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations.
Adjusted EBITDA represents amounts prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and adjusts for certain items that management believes are not reflective of the operational performance of the business. Consolidated adjusted EBITDA represents net income (loss), adjusted for interest expense, net, taxes, depreciation and amortization and certain items that management believes are not reflective of the operational performance of the business and additional adjustments. These adjustments include, but are not limited to, restructuring charges, net; non-restructuring impairment charges; discontinued operations; changes in fair value of contingent consideration obligations; significant legal and environmental charges; divestitures; separation costs; unrealized gain on equity investment; research & development upfront payments; reorganization items, net; share-based compensation and other items identified by the Company.
Segment net sales growth on a constant-currency basis measures the change in segment net sales between current- and prior-year periods using a constant currency, the exchange rate in effect during the applicable prior-year period.
The Company has provided these adjusted financial measures because they are used by management, along with financial measures in accordance with GAAP, to evaluate the company's operating performance. In addition, the Company believes that they will be used by certain investors to measure Mallinckrodt's operating results. Management believes that presenting these adjusted measures provides useful information about the Company's performance across reporting periods on a consistent basis by excluding items that the Company does not believe are indicative of its core operating performance. Reconciliations of these financial measures to the most directly comparable GAAP financial measures are included in Exhibit 99.1.
These adjusted measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP.

Item 9.01    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Exhibit
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document).




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MALLINCKRODT PLC
(registrant)
Date:March 15, 2022By: /s/ Bryan M. Reasons
Bryan M. Reasons
Executive Vice President and Chief Financial Officer
(principal financial and accounting officer)



Document

Exhibit 99.1

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)
Three Months Ended 1
December 31,
2021
Percent of
Net sales
December 25,
2020
Percent of
Net sales
Net sales
$597.2 100.0 %$682.8 100.0 %
Cost of sales358.7 60.1 372.3 54.5 
Gross profit238.5 39.9 310.5 45.5 
Selling, general and administrative expenses173.5 29.1 200.9 29.4 
Research and development expenses38.9 6.5 65.0 9.5 
Restructuring charges, net9.4 1.6 21.7 3.2 
Non-restructuring impairment charges90.4 15.1 — — 
Gains on divestiture— — (6.5)(1.0)
Opioid-related litigation settlement gain— — (9.3)(1.4)
Operating (loss) income(73.7)(12.3)38.7 5.7 
Interest expense(61.9)(10.4)(60.2)(8.8)
Interest income— — 0.5 0.1 
Other income, net6.1 1.0 6.3 0.9 
Reorganization items, net(99.0)(16.6)(61.4)(9.0)
Loss from continuing operations before income taxes(228.5)(38.3)(76.1)(11.1)
Income tax (benefit) expense(24.4)(4.1)78.1 11.4 
Loss from continuing operations(204.1)(34.2)(154.2)(22.6)
Income from discontinued operations, net of income taxes0.1 — 1.3 0.2 
Net loss$(204.0)(34.2)%$(152.9)(22.4)%
Basic loss per share:
Loss from continuing operations$(2.41)$(1.82)
Income from discontinued operations— 0.02 
Net loss$(2.41)$(1.81)
Diluted loss per share:
Loss from continuing operations$(2.41)$(1.82)
Income from discontinued operations— 0.02 
Net loss$(2.41)$(1.81)
Weighted-average number of shares outstanding
Basic weighted-average shares outstanding84.784.6
Diluted weighted-average shares outstanding84.784.6
(1)The Company reports its results based on a "52-53 week" year ending on the last Friday of December. The three months ended December 31, 2021 refers to the fourteen week period ended December 31, 2021 and the three months ended December 25, 2020 refers to the thirteen week period ended December 25, 2020.



1


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONSOLIDATED ADJUSTED EBITDA
(unaudited, in millions)
Three Months Ended
December 31, 2021December 25, 2020
Gross ProfitSG&AR&DAdjusted EBITDAGross ProfitSG&AR&DAdjusted EBITDA
Net loss$238.5 $173.5 $38.9 $(204.0)$310.5 $200.9 $65.0 $(152.9)
Adjustments:
Interest expense, net— — — 61.9 — — — 59.7 
Income taxes— — — (24.4)— — — 78.1 
Depreciation(1)
18.1 (4.2)(2.1)24.4 17.7 (18.8)(1.8)38.3 
Amortization144.4 (0.9)— 145.3 170.6 (0.8)— 171.4 
Restructuring charges, net— — — 9.4 — — — 21.7 
Non-restructuring impairment charge— — — 90.4 — — — — 
Income from discontinued operations— — — (0.1)— — — (1.3)
Change in contingent consideration fair value— (0.2)— 0.2 — (7.5)— 7.5 
Significant legal and environmental charges (2)
— (34.3)— 34.3 0.9 (2.6)— (5.8)
Gains on divestiture— — — — — — — (6.5)
Separation costs— (0.2)— 0.2 — (18.4)— 18.4 
Unrealized gain on equity investment— — — 0.1 — — — (1.6)
Reorganization items, net— — — 99.0 — — — 61.4 
Share-based compensation 0.1 (1.5)(0.2)1.8 0.4 (6.0)(1.3)7.7 
Japanese consumption tax credit— — — (6.8)— — — — 
As adjusted:$401.1 $132.2 $36.6 $231.7 $500.1 $146.8 $61.9 $296.1 
(1)Includes $0.1 million and $12.3 million of accelerated depreciation in selling general and administrative expenses ("SG&A") related to restructuring charges incurred during the three months ended December 31, 2021 and December 25, 2020, respectively.
(2)Represents an increase in environmental liabilities during the three months ended December 31, 2021. The three months ended December 25, 2020 includes a $9.3 million decrease in the fair value of the opioid settlement warrants, partially offset by $2.6 million in opioid defense costs and a $0.9 million change to the retrospective Medicaid lawsuit liability.



2


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
SEGMENT OPERATING INCOME
(unaudited, in millions)
Three Months Ended
December 31,
2021
December 25,
2020
Specialty Brands$224.2 $250.7 
Specialty Generics34.1 50.9 
Segment operating income258.3 301.6 
Unallocated amounts:
Corporate and unallocated expenses (1)
(60.5)(13.8)
Depreciation and amortization(169.7)(209.7)
Share-based compensation(1.8)(7.7)
Restructuring charges, net(9.4)(21.7)
Non-restructuring impairment charges(90.4)— 
Separation costs(0.2)(18.4)
Opioid-related litigation settlement gain— 9.3 
Medicaid lawsuit— (0.9)
Operating (loss) income$(73.7)$38.7 
(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
3


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
Three Months Ended
December 31,
2021
December 25,
2020
Percent
change
Currency impactConstant-currency growth
Specialty Brands$397.4 $506.6 (21.6)%(0.1)%(21.5)%
Specialty Generics199.8 177.1 12.8 0.1 12.7 
Segment net sales597.2 683.7 (12.7)(0.1)(12.6)
Medicaid lawsuit— (0.9)***
Net sales$597.2 $682.8 (12.5)%(0.1)%(12.4)%
*Not meaningful
MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
SELECT PRODUCT LINE NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
Three Months Ended
December 31,
2021
December 25,
2020
Percent
change
Currency impactConstant-currency growth
Specialty Brands
Acthar Gel$169.7 $191.3 (11.3)%— %(11.3)%
INOmax110.2 135.6 (18.7)— (18.7)
Ofirmev4.9 60.5 (91.9)— (91.9)
Therakos68.7 64.5 6.5 (0.9)7.4 
Amitiza41.1 50.6 (18.8)— (18.8)
Other2.8 4.1 (31.7)— (31.7)
Specialty Brands Total397.4 506.6 (21.6)(0.1)(21.5)
Specialty Generics
Hydrocodone (API) and hydrocodone-containing tablets22.0 26.1 (15.7)— (15.7)
Oxycodone (API) and oxycodone-containing tablets19.0 20.4 (6.9)— (6.9)
Acetaminophen (API)69.1 58.5 18.1 — 18.1 
Other controlled substances84.8 66.1 28.3 0.2 28.1 
Other4.9 6.0 (18.3)— (18.3)
Specialty Generics Total199.8 177.1 12.8 0.1 12.7 
Segment net sales597.2 683.7 (12.7)(0.1)(12.6)
Medicaid lawsuit— (0.9)***
Net sales$597.2 $682.8 (12.5)%(0.1)%(12.4)%
*Not meaningful



4


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)
Fiscal Year 1
December 31,
2021
Percent of
Net sales
December 25,
2020
Percent of
Net sales
Net sales (includes refined estimate of the retrospective one-time charge of $536.0 related to the Medicaid lawsuit for the fiscal year ended December 25, 2020)
$2,208.8 100.0 %$2,213.4 100.0 %
Cost of sales1,317.1 59.6 1,544.0 69.8 
Gross profit891.7 40.4 669.4 30.2 
Selling, general and administrative expenses581.8 26.3 884.1 39.9 
Research and development expenses205.2 9.3 290.8 13.1 
Restructuring charges, net26.9 1.2 37.5 1.7 
Non-restructuring impairment charges154.9 7.0 63.5 2.9 
Losses (gains) on divestiture0.8 — (16.6)(0.7)
Opioid-related litigation settlement loss (gain)125.0 5.7 (43.4)(2.0)
Medicaid lawsuit— — 105.1 4.7 
Operating loss(202.9)(9.2)(651.6)(29.4)
Interest expense(222.6)(10.1)(261.1)(11.8)
Interest income1.9 0.1 5.9 0.3 
Other income, net22.0 1.0 7.4 0.3 
Reorganization items, net(428.2)(19.4)(61.4)(2.8)
Loss from continuing operations before income taxes
(829.8)(37.6)(960.8)(43.4)
Income tax (benefit) expense(106.3)(4.8)8.9 0.4 
Loss from continuing operations(723.5)(32.8)(969.7)(43.8)
Income from discontinued operations, net of income taxes
6.1 0.3 25.1 1.1 
Net loss$(717.4)(32.5)%$(944.6)(42.7)%
Basic loss per share:
Loss from continuing operations$(8.54)$(11.48)
Income from discontinued operations0.07 0.30 
Net loss$(8.47)$(11.18)
Diluted loss per share:
Loss from continuing operations$(8.54)$(11.48)
Income from discontinued operations0.07 0.30 
Net loss$(8.47)$(11.18)
Weighted-average number of shares outstanding:
Basic84.784.5
Diluted84.784.5
(1)The Company reports its results based on a "52-53 week" year ending on the last Friday of December. Fiscal 2021 consisted of 53 weeks and fiscal 2020 consisted of 52 weeks.
5


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
CONSOLIDATED ADJUSTED EBITDA
(unaudited, in millions)
Fiscal Year
December 31, 2021December 25, 2020
Gross ProfitSG&AR&DAdjusted EBITDAGross ProfitSG&AR&DAdjusted EBITDA
Net loss$891.7 $581.8 $205.2 $(717.4)$669.4 $884.1 $290.8 $(944.6)
Adjustments:
Interest expense, net— — — 220.7 — — — 255.2 
Income taxes— — — (106.3)— — — 8.9 
Depreciation(1)
70.3 (17.6)(6.8)94.7 71.9 (35.1)(7.0)114.0 
Amortization577.7 (3.4)— 581.1 767.8 (3.4)— 771.2 
Restructuring charges, net— — — 26.9 — — — 37.5 
Non-restructuring impairment charge— — — 154.9 — — — 63.5 
Income from discontinued operations— — — (6.1)— — — (25.1)
Change in contingent consideration fair value— 7.4 — (7.4)— (9.9)— 9.9 
Significant legal and environmental charges (2)
— (34.3)— 159.3 536.0 (55.7)— 653.4 
Losses (gains) on divestiture— — — 0.8 — — — (16.6)
Separation costs— (1.2)— 1.2 — (93.4)— 93.4 
Unrealized gain on equity investment— — — (4.7)— — — (3.8)
R&D upfront payment— — — — — — (5.0)5.0 
Reorganization items, net— — — 428.2 — — — 61.4 
Share-based compensation0.5 (8.1)(1.6)10.2 1.3 (19.9)(4.1)25.3 
Japanese consumption tax credit— — — (6.8)— — — — 
As adjusted:$1,540.2 $524.6 $196.8 $829.3 $2,046.4 $666.7 $274.7 $1,108.6 
(1)Includes $2.1 million and $12.3 million of accelerated depreciation in SG&A related to restructuring charges incurred during fiscal 2021 and 2020, respectively.
(2)Fiscal 2021 includes a $125.0 million charge related to the opioid-related litigation settlement liability and a $34.3 million increase in environmental liabilities. Fiscal 2020 includes a retrospective one-time charge of $641.1 million (the "Acthar Gel Medicaid Retrospective Rebate"), of which $536.0 million and $105.1 million have been reflected as a component of net sales and operating expenses, respectively, in the condensed consolidated statement of operations. The $105.1 million reflected as a component of operating expenses represents a pre-acquisition contingency related to the portion of the Acthar Gel Medicaid Retrospective Rebate that arose from sales of Acthar Gel prior to the Company’s acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Fiscal 2020 also includes $55.7 million of opioid defense costs, partially offset by a $43.4 million decrease in the fair value of the opioid settlement warrants.

6


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
SEGMENT OPERATING INCOME
(unaudited, in millions)
Fiscal Year
December 31,
2021
December 25,
2020
Specialty Brands$812.8 $1,015.7 
Specialty Generics107.9 206.4 
Segment operating income920.7 1,222.1 
Unallocated amounts:
Corporate and unallocated expenses (1)
(129.6)(166.1)
Depreciation and amortization(675.8)(885.2)
Share-based compensation(10.2)(25.3)
Restructuring charges, net(26.9)(37.5)
Non-restructuring impairment charges(154.9)(63.5)
Separation costs(1.2)(93.4)
R&D upfront payment— (5.0)
Opioid-related litigation settlement (loss) gain(125.0)43.4 
Medicaid lawsuit— (641.1)
Operating loss$(202.9)$(651.6)
(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

7


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
Fiscal Year
December 31,
2021
December 25,
2020
Percent
change
Currency impactConstant-currency growth
Specialty Brands$1,547.0 $2,059.6 (24.9)%0.2 %(25.1)%
Specialty Generics661.8 689.8 (4.1)0.1 (4.2)
Segment net sales2,208.8 2,749.4 (19.7)0.2 (19.9)
Medicaid lawsuit— (536.0)***
Net sales$2,208.8 $2,213.4 (0.2)%0.2 %(0.4)%
*Not meaningful
MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
SELECT PRODUCT LINE NET SALES
(unaudited, in millions)
Fiscal Year
December 31,
2021
December 25,
2020
Percent
change
Currency impactConstant-currency growth
Specialty Brands
Acthar$593.6 $767.9 (22.7)%— %(22.7)%
INOmax448.5 574.1 (21.9)0.1 (22.0)
Ofirmev28.9 276.5 (89.5)— (89.5)
Therakos266.5 238.6 11.7 1.3 10.4 
Amitiza196.9 188.8 4.3 — 4.3 
Other12.6 13.7 (8.0)— (8.0)
Specialty Brands Total1,547.0 2,059.6 (24.9)0.2 (25.1)
Specialty Generics
Hydrocodone (API) and hydrocodone-containing tablets82.7 98.0 (15.6)— (15.6)
Oxycodone (API) and oxycodone-containing tablets68.5 68.4 0.1 — 0.1 
Acetaminophen (API)215.9 213.0 1.4 — 1.4 
Other controlled substances272.7 289.9 (5.9)0.3 (6.2)
Other22.0 20.5 7.3 — 7.3 
Specialty Generics Total661.8 689.8 (4.1)0.1 (4.2)
Segment net sales2,208.8 2,749.4 (19.7)0.2 (19.9)
Medicaid lawsuit— (536.0)***
Net sales$2,208.8 $2,213.4 (0.2)%0.2 %(0.4)%
*Not meaningful
8


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)
December 31,
2021
December 25,
2020
Assets
Current Assets:
Cash and cash equivalents$1,345.0 $1,070.6 
Accounts receivable, net439.1 538.8 
Inventories347.2 344.9 
Prepaid expenses and other current assets178.3 350.0 
Total current assets2,309.6 2,304.3 
Property, plant and equipment, net776.0 833.1 
Intangible assets, net5,448.4 6,184.5 
Other assets382.3 393.5 
Total Assets$8,916.3 $9,715.4 
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt$1,388.9 $3,587.9 
Accounts payable123.0 93.3 
Accrued payroll and payroll-related costs84.6 79.4 
Accrued interest17.0 26.9 
Accrued and other current liabilities328.7 331.2 
Total current liabilities1,942.2 4,118.7 
Pension and postretirement benefits30.1 34.6 
Environmental liabilities43.0 59.8 
Deferred income taxes20.9 80.6 
Other income tax liabilities83.2 100.1 
Other liabilities85.8 109.8 
Liabilities subject to compromise6,397.7 4,192.6 
Total Liabilities8,602.9 8,696.2 
Shareholders' Equity:
Preferred shares— — 
Ordinary shares
18.9 18.8 
Ordinary shares held in treasury at cost(1,616.1)(1,616.1)
Additional paid-in capital5,597.8 5,587.6 
Retained deficit(3,678.9)(2,961.5)
Accumulated other comprehensive loss(8.3)(9.6)
Total Shareholders' Equity313.4 1,019.2 
Total Liabilities and Shareholders' Equity$8,916.3 $9,715.4 


9


MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
(IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
Fiscal Year
December 31,
2021
December 25,
2020
Cash Flows From Operating Activities:
Net loss$(717.4)$(944.6)
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization675.8 885.2 
Share-based compensation10.2 25.3 
Deferred income taxes(59.9)385.3 
Non-cash impairment charges154.9 63.5 
Inventory provisions11.5 18.5 
Losses (gains) on divestiture0.8 (16.6)
Other non-cash items(13.1)(40.2)
Reorganization items, net22.5 10.2 
Changes in assets and liabilities:
Accounts receivable, net98.2 37.9 
Inventories(14.0)(51.1)
Accounts payable(1.1)15.7 
Income taxes108.5 (433.8)
Opioid-related litigation settlement liability125.0 — 
Medicaid lawsuit(4.2)638.9 
Other57.7 (95.3)
Net cash from operating activities455.4 498.9 
Cash Flows From Investing Activities:
Capital expenditures(55.3)(47.7)
Proceeds (payments) related to divestiture, net of cash15.7 (0.7)
Other1.8 37.2 
Net cash from investing activities(37.8)(11.2)
Cash Flows From Financing Activities:
Repayment of external debt(137.5)(139.5)
Debt financing costs— (9.4)
Repurchase of shares— (0.4)
Other— (36.3)
Net cash from financing activities(137.5)(185.6)
Effect of currency rate changes on cash(1.9)2.3 
Net change in cash, cash equivalents and restricted cash278.2 304.4 
Cash, cash equivalents and restricted cash at beginning of period1,127.0 822.6 
Cash, cash equivalents and restricted cash at end of period$1,405.2 $1,127.0 
Cash and cash equivalents at end of period$1,345.0 $1,070.6 
Restricted cash included in prepaid expenses and other assets at end of period24.0 20.2 
Restricted cash included in other long-term assets at end of period36.2 36.2 
Cash, cash equivalents and restricted cash at end of period$1,405.2 $1,127.0 
10